The Start-Up has closed an oversubscribed Series A financing round worth over four million Swiss francs with leading investors in the Life Sciences and IT sector.
B-rayZ has closed an oversubscribed Series A financing round worth over four million Swiss francs with leading investors in the Life Sciences and IT sector. This financing round has been made possible by LifeCare Partners, Protagon AG, and Convergence Partners and joined by the Eckenstein-Geigy-Foundation, the Swisspreneur association, and several private investors. B-rayZ’s AI revolutionizes radiological diagnostics supporting millions of women worldwide. The artificial intelligence start-up has developed the “b-box” to automatically determine breast cancer screenings’ image quality. This development significantly increases patients’ quality of life and physicians’ efficiency. With the closing of the Series A financing round, they will be able to accelerate their plans to expand sales in other European markets, reach FDA approval for the USA, and develop new products for gynecologists and radiologists based on their proprietary AI platform.
“We invested in b-rayZ because we believe that the importance of digital health is growing globally, they have one of the best AI teams in the world, but also because they have such a deep understanding of radiology and the clinical validation required to herald in this new era of cancer diagnosis,” asserts Severin Weiss, Chairman and founder of Protagon AG.
Read more about b-rayZ: https://www.b-rayz.ch/